Overall, the IL-27+cabo combination therapy appeared to increase the infiltration of pro-inflammatory and anti-tumor immune effectors that could exert an anti-tumorigenic effect, decrease the presence of regulatory immune cells, and potentially inhibit angiogenesis within the tumor microenvironment. Here, IL27 is linked to neoplasm.